drugset / Trial / NCT04935515

C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.

NCT04935515

Non-randomizedParallel-groupOpen-labelSupportive care

Summary

During the peak of the second COVID -19 wave, the hospitals were over-crowded. Many COVID -19 positive patients had to stay at home and reach out to their family physicians for guidance. Medical follow-up for these patients was a daunting challenge. As in - patient hospital facilities were not readily accessible due to over crowding, early objective tests to identify home quarantined patients prone to deterioration and timely medical intervention to avoid hospitalization were required. Based on early assessment of inflammatory markers like CRP and clinical signs like persistent high-grade fever, need-based early medical intervention was initiated in home quarantined COVID -19 patients prior to the onset of hypoxia, in order to avoid complications and hospitalization

Timeline

Start
2021-04-15
Primary completion
2021-05-09
Completion
2021-06-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetaminophen Small molecule Oral
Subject Azithromycin Small molecule Oral
Subject Ceftriaxone Other / unclassified Intravenous
Subject Cetirizine Other / unclassified Oral
Subject Dexamethasone Small molecule Intravenous
Subject Methylprednisolone Other / unclassified Oral
Subject Rivaroxaban Other / unclassified Oral
Subject Vitamin C Other / unclassified Oral
Subject Vitamin D Other / unclassified Oral
Subject Zinc Sulfate Unknown Oral

Indications